Endogenous activated protein C predicts hemorrhagic transformation and mortality after tissue plasminogen activator treatment in stroke patients

Cerebrovascular Diseases

Volumn 28, Issue 2, 2009, Pages 143-150

  Mendioroz, Maite ^a   Fernández Cadenas, Israel ^a   Alvarez Sabín, José ^a   Rosell, Anna ^a   Quiroga, Dorita ^a   Cuadrado, Eloy ^a   Delgado, Pilar ^a   Rubiera, Marta ^a   Ribó, Marc ^a   Molina, Carlos ^a   Montaner, Joan ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Activated protein C; Coagulation; Plasmin; Stroke; Thrombolysis

Indexed keywords

ACTIVATED PROTEIN C; SERINE PROTEINASE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CELL PROTECTION; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY; MORTALITY; PRIORITY JOURNAL; RANKIN SCALE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; INFUSIONS, INTRAVENOUS; INTRACRANIAL HEMORRHAGES; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROTEIN C; RISK ASSESSMENT; ROC CURVE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; UP-REGULATION;

EID: 67449113445     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000225907     Document Type: Article

References (42)

1. NINDS tPA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;222:1581-1587.
2. IMS II Trial Investigators: The Interventional Management of Stroke (IMS) II study. Stroke 2007;38:2127-2135.
3. Alexandrov AV, Grotta JC: Arterial re-occlusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002;59:862-867.
4. NINDS tPA Stroke Study Group: Intracerebral hemorrhage after intravenous rt-PA therapy for ischemic stroke. Stroke 1997;28:2029-2118.
5. Wang YF, Tsirka SE, Strickland S, et al: Tissue plasminogen activator (tPA) increases neuronal damage after local cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 1998;4:228-231. (Pubitemid 28138083)
6. Matys T, Strickland S: Tissue plasminogen activator and NMDA receptor cleavage. Nat Med 2003;9:371-373.
7. Nicole O, Docagne F, Ali C, et al: The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001;7:59-64. (Pubitemid 32095643)
8. Joyce DE, Gelbert L, Ciaccia A, et al: Gene expression profile of anti-thrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001;276:11199-11203. (Pubitemid 38089304)
9. Riewald M, Petrovan RJ, Donner A, et al: Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002;296:1880-1882. (Pubitemid 34596276)
10. Cheng T, Liu D, Griffin JH, et al: Activated protein C prevents neuronal apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003;9:338-342.
11. Guo H, Liu D, Gelbard H, et al: Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron 2004;41:563-572. (Pubitemid 38253068)
12. Feistrietzer C, Riewald M: Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005;105:3178-3184. (Pubitemid 40504337)
13. Liu D, Cheng T, Guo H, et al: Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med 2004;10:1379-1383. (Pubitemid 40022721)
14. Cheng T, Petraglia AL, Li Z, et al: Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med 2006;12:1278-1285. (Pubitemid 44706930)
15. Adams HP, Bendixen BH, Kappelle LJ, et al: 3rd classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
16. Brott TG, Haley EC, Levy DE, et al: Urgent therapy for stroke. I. Pilot study of tissue plasminogen activator administered within 90 min. Stroke 1992;23:632-640.
17. Demchuk AM, Burgin WS, Christou I, et al: Thrombolysis in brain ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator. Stroke 2001;32:89-93. (Pubitemid 32063829)
18. Zanette EM, Roberti C, Mancini G, et al: Spontaneous middle cerebral artery reperfusion in ischemic stroke: a follow-up study with transcranial Doppler. Stroke 1995;26:430-433.
19. Hacke W, Kaste M, Fieschi C, et al: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025.
20. Pessin M, del Zoppo G, Estol C: Thrombolytic agents in the treatment of stroke. Clin Neuropharmacol 1990;13:271-289.
21. Aygun N, Masaryk TJ: Diagnostic imaging for intracerebral hemorrhage. Neurosurg Clin N Am 2002;13:313-334.
22. Holscher T, Schlachetzki F, Zimmermann M, Jakob W, Ittner KP, Haslberger J, Bogdahn U, Boy S: Transcranial ultrasound from diagnosis to early stroke treatment. 1. Feasibility of prehospital cerebrovascular assessment. Cerebrovasc Dis 2008;26:659-663.
23. Kaps M, Stolz E, Allendoerfer J: Prognostic value of transcranial sonography in acute stroke patients. Eur Neurol 2008;59(suppl 1):9-16.
24. Esmon CT: The protein C pathway. Chest 2003;124:26-32.
25. Bajzar L, Nesheim ME, Tracy PB: The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996;88:2093-2100. (Pubitemid 26307911)
26. Salata Y, Curriden S, Lawrence D, et al: Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci USA 1985;82:1121-1125. (Pubitemid 15100506)
27. Koster T, Rosendaal FR, Briët E, et al: Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995;85:2756-2761.
28. Inoue H, Nozawa T, Okumura K, Jong-Dae L, Shimizu A, Yano K: Prothrombotic activity is increased in patients with nonvalvular atrial fibrillation and risk factors for embolism. Chest 2004;126:687-692. (Pubitemid 39258018)
29. Mosnier LO, Zlokovic BV, Griffin JH: The cytoprotective protein C pathway. Blood 2007;109:3161-3172.
30. Yang L, Bae JS, Manithody C, et al: Identification of a specific exosite on activated protein C for interaction with protease-activated receptor 1. J Biol Chem 2007;282:25493-25500. (Pubitemid 47372792)
31. Feistritzer C, Riewald M: Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005;105:3178-3184. (Pubitemid 40504337)
32. Shibata M, Kumar SR, Amar A, et al: Antiinflammatory, antithrombotic and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation 2001;103:1799-1805. (Pubitemid 32291419)
33. Fernandez JA, Xu X, Liu D, et al: Recombinant murine activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells Mol Dis 2003;30:271-276. (Pubitemid 36539428)
34. Esmon CT: Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006;32:49-60.
35. Griffin JH, Fernandez JA, Mosnier LO, et al: The promise of protein C. Blood Cells Mol Dis 2006;36:211-216.
36. Kerschen EJ, Fernandez JA, Cooley BC, Yang XV, Sood R, Mosnier LO, Castellino FJ, Mackman N, Griffin JH, Weiler H: Endotoxemia and sepsis mortality reduction by nonanticoagulant activated protein C. J Exp Med 2007;204:2439-2448. (Pubitemid 47529328)
37. Raivio P, Fernandez JA, Kuitunen A, et al: Activation of protein C and hemodynamic recovery after coronary artery bypass surgery. J Thorac Cardiovasc Surg 2007;133:44-51. (Pubitemid 46014242)
38. Takazoe K, Ogawa H, Yasue H, et al: Association of plasma levels of activated protein C with recanalization of the infarct-related coronary artery after thrombolytic therapy in acute myocardial infarction. Thromb Res 1999;95:37-47. (Pubitemid 29325259)
39. Zlokovic BV, Zhang C, Liu D, et al: Functional recovery after embolic stroke in rodents by activated protein C. Ann Neurol 2005;58:474-477. (Pubitemid 41266637)
40. Bernard GR, Vincent JL, Laterre PF, et al; Recombinant human protein C worldwide evaluation in severe sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
41. Martí-Carvajal A, Salanti G, Cardona AF: Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2008;23:CD004388. (Pubitemid 351807575)
42. Mosnier LO, Gale AJ, Yegneswaran S, et al: Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood 2004;104:1740-1744. (Pubitemid 39202282)